Identifies themes and clusters of stock movements
Market TodayThemes and Stocks AnalysesThematic Stock SearchClick here for daily refresh schedule
NTRP - Neurotrope, Inc.
$0.94
0.02(2.72%)4:22:50 PM 11/23/2020
Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company was founded on January 11, 2011 and is headquartered in New York, NY.
Stock Chart
leak data
No summary
leak data

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra
leak data

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

leak data

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
Peers

Related Peers

Stock news

    11/20/2020NTRP
    Neurotrope, Inc. Approves Spin-Off of Neurotrope Bioscience, Inc. and Sets Record and Distribution Dates

    Neurotrope, Inc. (NASDAQ: NTRP) ("Neurotrope" or the "Company") announced today that its Board of Directors has approved the conditional distribution and set the shareholder of record and distribution dates in connection with the previously announced spin-off (the "Spin-Off") of its wholly-owned subsidiary, Neurotrope Bioscience, Inc. ("NBI"). Subject to the closing of Neurotrope's proposed merger with Metuchen Pharmaceuticals, LLC ("Metuchen"), shareholders and certain warrant holders of record...

    11/2/2020NTRP
    Insider Buys Neurotrope Stock

    Neurotrope Inc (NASDAQ:NTRP) was trading 1.10% higher from the previous closing price. A Form 4 filing filed with the SEC on Monday, November 2 showed that Schechter Jonathan bought 25,000 shares at an average price of $0.98. The transaction moved the executive's stake in Neurotrope Inc. to 75,000 shares.The Importance of Insider Transactions While transactions from an insider shouldn't be used as the sole item to make an investment or trading decision, an insider buying or selling stock in thei...

    10/26/2020NTRP
    Insider Buys Neurotrope's Stock

    Neurotrope Inc (NASDAQ:NTRP) was trading 3.6% higher from the previous closing price. A Form 4 filing filed with the SEC on Monday, October 26 showed that Schechter Jonathan bought 25,000 shares at an average price of $1.10. The transaction moved the executive's stake in Neurotrope Inc. to 50,000 shares.The Importance of Insider Transactions While transactions from an insider shouldn't be used as the sole item to make an investment or trading decision, an insider buying or selling stock ...

    10/19/2020NTRP
    Insider Buys Neurotrope's Shares

    Neurotrope Inc (NASDAQ:NTRP) was trading 4.6% higher from the previous closing price. Silverman Joshua filed a Form 4 with the SEC on Monday, October 19. The insider bought 50,000 shares at an average price of $1.07. After the transaction, the executive's stake in Neurotrope Inc. moved to 50,000 shares.Why Insider Transactions Are Important? While transactions from an insider shouldn't be used as the sole item to make an investment or trading decision, an insider buying or selling stock in their...

    10/6/2020NTRP
    Neurotrope Announces First Patient Dosed in Long-Term Clinical Trial of Bryostatin in Alzheimer's Disease

    Neurotrope, Inc. (Nasdaq: NTRP) today announced dosing of the first patient in its ongoing, long-term Phase 2 study of Bryostatin-1 for the treatment of Alzheimer's disease ("AD"). The study will be conducted in collaboration with the National Institutes of Health ("NIH") under a $2.7 million grant to Neurotrope.

    10/1/2020NTRP
    Neurotrope (NASDAQ:NTRP) Is In A Good Position To Deliver On Growth Plans

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

    09/30/2020NTRP
    Neurotrope Shareholders to Own 49 Percent of Petros Under Revised Merger Agreement with Metuchen

    Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company focused on innovative therapeutics for men's health conditions ("Metuchen"), today announced that they have entered into an amendment to their definitive merger agreement ("Amended Merger Agreement") under which the consideration due to Neurotrope stockholders will increase to 49% of the combined company on a pro forma basis and based upon the final Neurotrope common stock share count...

    06/24/2020NTRP
    Neurotez: Can Leptin Prove Beneficial for Alzheimer's Patients?

    By Anita Dushyanth, PhD NASDAQ:INMB | NASDAQ:NTRP | TSX:PMN.TO Rethinking the approach to treat Alzheimer’s disease Both scientists and physicians are still wrestling with the idea of how to identify the biological drivers that are responsible for the early onset of neurodegenerative diseases. Alzheimer’s disease (AD), in particular, is extremely challenging to treat because it develops slowly